The report provides an in depth analysis of the US drug eluting sinus stent (DESS) market by value. The report also provides a detailed analysis of the US sinus surgery market by sinusitis patients, chronic sinusitis patients, number of ENT eligible patients, number of procedures, etc. The report also provides an analysis of the US Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD) market by Value and by number of procedures.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the US drug eluting sinus stent (DESS) market has also been forecasted till the period 2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region. The key players of the drug eluting sinus stent (DESS) market are Intersect ENT, Inc., Medtronic plc, Stryker Corporation (Entellus Medical, Inc.), and Johnson & Johnson (Acclarent, Inc.) are also profiled with their financial information and respective business strategies.
The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the US drug eluting sinus stent (DESS) market has also been forecasted till the period 2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.
The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region. The key players of the drug eluting sinus stent (DESS) market are Intersect ENT, Inc., Medtronic plc, Stryker Corporation (Entellus Medical, Inc.), and Johnson & Johnson (Acclarent, Inc.) are also profiled with their financial information and respective business strategies.
Country Coverage
- The US
Company Coverage
- Intersect ENT, Inc
- Medtronic plc
- Stryker Corporation (Entellus Medical, Inc.)
- Johnson & Johnson (Acclarent, Inc.)
Table of Contents
1. Executive Summary
2. Introduction
3. The US Market Analysis
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
List of Figures
Executive Summary
Sinusitis can be divided into Acute Sinusitis, Recurrent Acute Rhinosinusitis (RARS) and chronic Rhinosinusitis (CRS), on the basis of the duration of the episode of sinusitis and its severity. The treatment options for the sinusitis can be over-the-counter treatment, medical management and surgery. The OTC treatment includes decongestants, antihistamines, pain relievers and nasal irrigation. Medical management includes antibiotics and oral and nasal steroids. The sinus surgeries are mainly of two types: Functional Endoscopic Sinus Surgery (FESS) and Balloon Sinus Dilation (BSD).The US drug eluting sinus stent (DESS) market has increased significantly during the recent years, and projections are made that the market would rise in the next few years. The drug eluting sinus stent (DESS) market is expected to increase due to surging healthcare expenditure, increasing prevalence of sinus related disorders, growing treatment in physician’s office, limitations of FESS, favorable government initiatives for promoting the use of sinus stents, etc. Yet the market faces some challenges such as economic slowdown, high cost involved, use of oral steroids and packing material, etc.
Companies Mentioned
- Intersect ENT, Inc
- Medtronic plc
- Stryker Corporation (Entellus Medical, Inc.)
- Johnson & Johnson (Acclarent, Inc.)
